A South Oakland company targeting the eye care market has reported that in preclinical tests, a medication appears to significantly reduce damage to the optic nerve, raising the possibility it could be an effective treatment for eye disease and injury.

Noveome Biotherapeutics’ new product is at least three years from reaching the market, but the company recently published results of the trial showing that treatment with ST266, as the drug is currently called, reduced optic nerve damage in mice.

The study, published in the journal Investigative Ophthalmology and Visual Science, indicates the drug may have applications in neurodegenerative diseases including traumatic brain injury; chronic traumatic encephalopathy, the brain disorder associated with concussions; and Alzheimer’s disease.

Protecting the optic nerve could have broad implications in eye care. The optic nerve doesn’t heal or regenerate after damage, and forecasts call for 111.8 million people to have glaucoma by 2040, which leads to blindness by damaging the optic nerve, according to research done in 2014.

Advertise with us

At least two clinical trials are needed before ST266 is submitted to the Food and Drug Administration for approval, company officials said. The medication, which had both protective and anti-inflammatory properties in early testing, is derived from human placental cells extracted after birth.

William Golden founded Noveome in 2000 and now serves as chairman and CEO of the company, which employs 30 and also has an office in Florida. The company has raised $114 million, mostly from government agencies, but does not yet have sales revenue.

Previously, Mr. Golden worked in venture capital at Boston University and corporate finance at Dravo Corp. and Trammell Crow. He has an MBA from Harvard Business School and a Bachelor of Science in mechanical engineering from the University of Notre Dame.

The new medicine’s effect in humans is uncertain, but no treatments exist to protect the nerve, which transfers visual information to the brain from the retina of the eye.

“It’s neuroprotective,” Larry Brown, chief scientific officer, said. “It’s been very convincing.”

Advertise with us

Noveome’s drug is administered deep into the nasal cavity, passing through the blood-brain barrier, a semipermeable barrier that separates circulating blood from the brain. Noveome plans to begin a phase 1 clinical safety trial of the medication later this year in collaboration with SipNose, an Israeli medical device maker.

Finding an agent that protects or restores the optic nerve has been the holy grail of ophthalmology for at least a decade, said Richard A. Lewis, a glaucoma researcher and co-founder of Capital City Surgery Center and Sacramento Eye Consultants.

The search included the $100 million research failure of the drug memantine in 2008 by pharmaceutical company Allergan Inc. of Irvine, Calif. Although a second phase 3 clinical trial found that memantine slowed progression of glaucoma, there was no significant benefit to the patient when compared to a placebo.

Part of the difficulty in getting FDA approval is the agency’s requirement that new eye medicines improve vision, Dr. Lewis said.

Still, protecting the optic nerve is an active area of research and much has changed since Allergan stopped the memantine trial a decade ago.

Advertise with us

“I think we have more insights to it now,” Dr. Lewis said. “It’s a work in progress, and I think we’re making more progress than ever.”

Kris B. Mamula: kmamula@post-gazette.com or 412-263-1699